STAT44%
ARPA-H invests $160 million to make custom gene editing routine 33%
By Jason Mast88%
7/9/2026, 8:00:00 AM
BS Summary: This article contains 8 faulty reasoning types, including Framing Effect, Loss Aversion, and Negativity Bias, with Attempt to Sell a Product or Service as the most egregious example at 45.4% saturation with 128 hits. Analysis detected 271 faulty-reasoning hits from 282 analyzed words, generating a BS Score of 41.7% and a BS Rank of 33% (14,656 of 21,887 articles). This article is better (less manipulative) than 67.00% of the article peer group.
ARPA-H launches $160 million effort to develop custom gene editing drugs
Program will fund seven groups over five years in hope of Baby KJ-like successes
Jean-Christophe VERHAEGEN / AFP via Getty Images
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.
Confidential tips can be sent on Signal at JasonMast.77.
ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.
The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.
Each team has a deadline of starting clinical trials by year three of the program, although some may start much sooner.
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology , CRISPR , gene editing , Gene therapy , HHS , rare diseases , STAT+
Submit a correction request Reprints
STAT Plus: Roche ends Huntington’s gene-silencing programs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug
STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere
Speakers
2speakers46%attributed speech152writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageSTAT+
88 attributed words68% of attributed speech41% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.